Windtree Therapeutics entered into an Asset Purchase Agreement to sell its cardiovascular drug candidates to Seismic Pharmaceutical Operations. Windtree will receive 20% of any future proceeds generated by Seismic, including potential global commercial net revenue in acute heart failure if approved. Windtree will also receive $700,000 if Seismic completes a financing of at least $10 million to fund development. As part of the deal, certain development payables related to the cardiovascular candidates will transfer to Seismic.
Agreement details:
- Agreement type: Asset purchase agreement for cardiovascular drug candidates
- Counterparty: Seismic Pharmaceutical Operations
- Signed / Effective: Dec 16 2025 / same
- Duration / Termination: N/A
- Reason: Monetize assets and shift development risk and liabilities
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.